Clarity Pharmaceuticals licenses University of Melbourne technology for prostate cancer treatment and imaging

Dec 07, 2017

International radiopharmaceutical company Clarity has licensed technology developed at the University of Melbourne for imaging and treating prostate cancer.

Cookies help us deliver our services. By using our services, you agree to our use of cookies.